Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Posted by George Bondi on Aug 26th, 2026

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Get Free Report) was the recipient of a significant decline in short interest during the month of August. As of August 14th, there was short interest totaling 4,812 shares, a decline of 80.6% from the July 30th total of 24,819 shares. Currently, 0.5% of the shares of the stock are short sold. Based on an average daily volume of 118,901 shares, the days-to-cover ratio is currently 0.0 days.

Institutional Trading of Biodexa Pharmaceuticals

A hedge fund recently bought a new stake in Biodexa Pharmaceuticals stock. Sabby Management LLC acquired a new stake in Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 190,658 shares of the company’s stock, valued at approximately $433,000. Biodexa Pharmaceuticals accounts for 0.6% of Sabby Management LLC’s investment portfolio, making the stock its 10th largest position. Sabby Management LLC owned 28.04% of Biodexa Pharmaceuticals as of its most recent SEC filing. 17.51% of the stock is currently owned by institutional investors.

Biodexa Pharmaceuticals Stock Down 14.7%

BDRX stock opened at $1.01 on Wednesday. The stock’s 50 day moving average price is $2.05 and its 200 day moving average price is $3.35. Biodexa Pharmaceuticals has a 1 year low of $0.99 and a 1 year high of $59.40.

Analyst Ratings Changes

Separately, Weiss Ratings raised Biodexa Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, June 18th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has an average rating of “Sell”.

View Our Latest Report on Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Company Profile

(Get Free Report)

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.